Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
oseltamivir carboxylate
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules
- Administration
- Oral (via Conversion From Oseltamivir Phosphate)
01
Overview
**Oseltamivir carboxylate** is the active metabolite of oseltamivir phosphate (marketed as Tamiflu), formed via hepatic hydrolysis after oral administration. It is a potent, selective inhibitor of the influenza virus enzyme neuraminidase, which is essential for viral replication and release from host cells. Oseltamivir carboxylate acts by competitively inhibiting the active site of neuraminidase, thereby halting the spread of infection within the respiratory tract. This leads to reduced viral titers, shortened symptom duration, and lower viral shedding in treated patients.
- Brand names
- TamifluEbilfumin
- Other names
- GS4071GS-4071GS 4071oseltamivir active metabolite
02
Targets
Neuraminidase
Beyond the preview
Go deeper on oseltamivir carboxylate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on oseltamivir carboxylate.